← FDA DRUG APPROVALS

FDA NDA · NDA212895

CONJUPRI

levamlodipine

Sponsor: CSPC OUYI

APPLICATION
NDA212895
TYPE
NDA
ORIGINAL APPROVAL
2019-12-19
LATEST ACTION
2019-12-19
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

CONJUPRI · ReferenceDiscontinued
LEVAMLODIPINE MALEATE EQ 2.5MG BASE · TABLET · ORAL
CONJUPRI · ReferenceDiscontinued
LEVAMLODIPINE MALEATE EQ 5MG BASE · TABLET · ORAL
CONJUPRI · ReferenceDiscontinued
LEVAMLODIPINE MALEATE EQ 1.25MG BASE · TABLET · ORAL

Approval history

2019-12-19Type 2 - New Active Ingredient and Type 3 - New Dosage Form · Original · standard — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →